<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_GPB578 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEmmc1 docx ?>
<?FILEmmc2 pptx ?>
<?FILEmmc3 pptx ?>
<?FILEmmc4 xlsx ?>
<?FILEmmc5 xlsx ?>
<?FILEmmc6 xlsx ?>
<?FILEmmc7 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genomics Proteomics Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genomics Proteomics Bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Genomics, Proteomics &amp; Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1672-0229</issn>
    <issn pub-type="epub">2210-3244</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8570443</article-id>
    <article-id pub-id-type="pii">S1672-0229(21)00226-6</article-id>
    <article-id pub-id-type="doi">10.1016/j.gpb.2021.09.006</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>COVID-ONE-hi: The One-stop Database for COVID-19-specific Humoral Immunity and Clinical Parameters</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Xu</surname>
          <given-names>Zhaowei</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
        <xref rid="af010" ref-type="aff">2</xref>
        <xref rid="fn1" ref-type="fn">#</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Li</surname>
          <given-names>Yang</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">#</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Lei</surname>
          <given-names>Qing</given-names>
        </name>
        <xref rid="af015" ref-type="aff">3</xref>
        <xref rid="fn1" ref-type="fn">#</xref>
      </contrib>
      <contrib contrib-type="author" id="au020">
        <name>
          <surname>Huang</surname>
          <given-names>Likun</given-names>
        </name>
        <xref rid="af020" ref-type="aff">4</xref>
        <xref rid="fn1" ref-type="fn">#</xref>
      </contrib>
      <contrib contrib-type="author" id="au025">
        <name>
          <surname>Lai</surname>
          <given-names>Dan-yun</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">#</xref>
      </contrib>
      <contrib contrib-type="author" id="au030">
        <name>
          <surname>Guo</surname>
          <given-names>Shu-juan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">#</xref>
      </contrib>
      <contrib contrib-type="author" id="au035">
        <name>
          <surname>Jiang</surname>
          <given-names>He-wei</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au040">
        <name>
          <surname>Hou</surname>
          <given-names>Hongyan</given-names>
        </name>
        <xref rid="af025" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au045">
        <name>
          <surname>Zheng</surname>
          <given-names>Yun-xiao</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au050">
        <name>
          <surname>Wang</surname>
          <given-names>Xue-ning</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au055">
        <name>
          <surname>Wu</surname>
          <given-names>Jiaoxiang</given-names>
        </name>
        <xref rid="af030" ref-type="aff">6</xref>
      </contrib>
      <contrib contrib-type="author" id="au060">
        <name>
          <surname>Ma</surname>
          <given-names>Ming-liang</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au065">
        <name>
          <surname>Zhang</surname>
          <given-names>Bo</given-names>
        </name>
        <xref rid="af025" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au070">
        <name>
          <surname>Chen</surname>
          <given-names>Hong</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au075">
        <name>
          <surname>Yu</surname>
          <given-names>Caizheng</given-names>
        </name>
        <xref rid="af035" ref-type="aff">7</xref>
      </contrib>
      <contrib contrib-type="author" id="au080">
        <name>
          <surname>Xue</surname>
          <given-names>Jun-biao</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au085">
        <name>
          <surname>Zhang</surname>
          <given-names>Hai-nan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au090">
        <name>
          <surname>Qi</surname>
          <given-names>Huan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au095">
        <name>
          <surname>Yu</surname>
          <given-names>Siqi</given-names>
        </name>
        <xref rid="af010" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au100">
        <name>
          <surname>Lin</surname>
          <given-names>Mingxi</given-names>
        </name>
        <xref rid="af010" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au105">
        <name>
          <surname>Zhang</surname>
          <given-names>Yandi</given-names>
        </name>
        <xref rid="af015" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au110">
        <name>
          <surname>Lin</surname>
          <given-names>Xiaosong</given-names>
        </name>
        <xref rid="af015" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au115">
        <name>
          <surname>Yao</surname>
          <given-names>Zongjie</given-names>
        </name>
        <xref rid="af015" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au120">
        <name>
          <surname>Sheng</surname>
          <given-names>Huiming</given-names>
        </name>
        <xref rid="af030" ref-type="aff">6</xref>
      </contrib>
      <contrib contrib-type="author" id="au125">
        <name>
          <surname>Sun</surname>
          <given-names>Ziyong</given-names>
        </name>
        <xref rid="af025" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au130">
        <name>
          <surname>Wang</surname>
          <given-names>Feng</given-names>
        </name>
        <email>fengwang@tjh.tjmu.edu.cn</email>
        <xref rid="af025" ref-type="aff">5</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au135">
        <name>
          <surname>Fan</surname>
          <given-names>Xionglin</given-names>
        </name>
        <email>xlfan@hust.edu.cn</email>
        <xref rid="af015" ref-type="aff">3</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au140">
        <name>
          <surname>Tao</surname>
          <given-names>Sheng-ce</given-names>
        </name>
        <email>taosc@sjtu.edu.cn</email>
        <xref rid="af005" ref-type="aff">1</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="af005"><label>1</label>Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China</aff>
      <aff id="af010"><label>2</label>Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China</aff>
      <aff id="af015"><label>3</label>Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China</aff>
      <aff id="af020"><label>4</label>Fujian Key Laboratory of Crop Breeding by Design, Key Laboratory of Genetics, Breeding and Multiple Utilization of Crops, Ministry of Education, Fujian Agriculture and Forestry University, Fuzhou 350028, China</aff>
      <aff id="af025"><label>5</label>Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China</aff>
      <aff id="af030"><label>6</label>Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China</aff>
      <aff id="af035"><label>7</label>Department of Public Health, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding authors. <email>fengwang@tjh.tjmu.edu.cn</email><email>xlfan@hust.edu.cn</email><email>taosc@sjtu.edu.cn</email></corresp>
      <fn id="fn1">
        <label>#</label>
        <p id="np010">Equal contribution.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>05</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="ppub">
      <month>10</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>05</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <volume>19</volume>
    <issue>5</issue>
    <fpage>669</fpage>
    <lpage>678</lpage>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>26</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>11</day>
        <month>10</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Authors</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="ab005">
      <p>Coronavirus disease 2019 (COVID-19), which is caused by <bold>SARS-CoV-2</bold>, varies with regard to symptoms and mortality rates among populations. <bold>Humoral immunity</bold> plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (named COVID-ONE-hi). COVID-ONE-hi is based on the data that contain the IgG/IgM responses to 24 full-length/truncated proteins corresponding to 20 of 28 known SARS-CoV-2 proteins and 199 spike protein peptides against 2360 serum samples collected from 783 COVID-19 patients. In addition, 96 clinical parameters for the 2360 serum samples and basic information for the 783 patients are integrated into the database. Furthermore, COVID-ONE-hi provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-hi is freely available at <ext-link ext-link-type="uri" xlink:href="http://www.COVID-ONE.cn" id="ir005">www.COVID-ONE.cn</ext-link>.</p>
    </abstract>
    <kwd-group id="kg005">
      <title>Keywords</title>
      <kwd>SARS-CoV-2</kwd>
      <kwd>Protein microarray</kwd>
      <kwd>Humoral immunity</kwd>
      <kwd>One-stop tool</kwd>
      <kwd>Shiny</kwd>
    </kwd-group>
  </article-meta>
  <notes>
    <p id="ms005">Handled by Zhang Zhang</p>
  </notes>
</front>
<body>
  <sec id="s0005">
    <title>Introduction</title>
    <p id="p0005">COVID-19 is an unprecedented global threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has already caused 209,308,033 infections and claimed 4,393,014 lives as of August 19, 2021 (<ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html" id="ir010">https://coronavirus.jhu.edu/map.html</ext-link>) <xref rid="b0005" ref-type="bibr">[1]</xref>. However, there is still no effective medicine <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref> for COVID-19.</p>
    <p id="p0010">Most patients recover via their own immunity, including SARS-CoV-2-specific IgG responses, especially neutralizing antibodies <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>. Overall, it is of great interest to decipher SARS-CoV-2-specific IgG/IgM responses at a system level and to correlate antibody responses to clinical parameters.</p>
    <p id="p0015">To understand how the human immune system responds to SARS-CoV-2, we constructed a SARS-CoV-2 proteome microarray containing 18 of the 28 predicted proteins and applied it to characterize IgG and IgM antibodies for the sera of 29 convalescent patients <xref rid="b0035" ref-type="bibr">[7]</xref>. Recently, we upgraded the SARS-CoV-2 protein microarray, and the new microarray contains 24 full-length/truncated proteins corresponding to 20 known SARS-CoV-2 proteins and 199 peptides fully covering the spike protein <xref rid="b0040" ref-type="bibr">[8]</xref>. Using this microarray, we screened 2360 serum samples from 783 COVID-19 patients, covering mild, severe, and critical cases. Thus, we compiled a dataset with comprehensive information on SARS-CoV-2-specific antibody responses and rich in clinical parameters.</p>
    <p id="p0020">To share the dataset efficiently, in addition to the related research that we have already published <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, we built a database for COVID-19-specific humoral immune responses and clinical parameters, namely, COVID-ONE-hi (<ext-link ext-link-type="uri" xlink:href="http://www.covid-one.cn" id="ir015">www.covid-one.cn</ext-link>), using Shiny. This database contains a comprehensive dataset of IgG and IgM responses to the 24 full-length/truncated proteins corresponding to 20 known SARS-CoV-2 proteins and 199 spike protein peptides from a cohort of 783 COVID-19 patients. To bolster clinical relevance, 96 clinical parameters and basic patient information are also included. COVID-ONE-hi provides search, data analysis, and visualization functions. In particular, COVID-ONE-hi integrates antibody response landscape analysis, correlation analysis, machine learning, <italic>etc.</italic> In the data analysis module, users can easily define sample group(s) of interest by adjusting scale bars, and the sample group can be either one group or paired groups. In-depth analysis is achieved by clicking a single button; optionally, the results can be saved and downloaded as an independent package for further analysis.</p>
    <p id="p0025">To our knowledge, COVID-ONE-hi is the first database for COVID-19-specific humoral immune responses. We believe that COVID-19 humoral immunity will be of broad interest and will facilitate understanding of immune responses in COVID-19 to combat the pandemic.</p>
  </sec>
  <sec id="s0010">
    <title>Implementation</title>
    <p id="p0030">COVID-ONE-hi is a Shiny (v1.5.0)-based database. Shiny dashboard (v0.7.1) and Shiny BS (v0.61) were used to shape the UI, and the package DT (v0.15) was used to format data tables. For data analysis, dplyr (v1.0.2), tidyverse (v1.3.0), randomForest (v4.6–14), pROC (v1.16.2), and umap (v0.2.6.0) were integrated into Shiny. Pheatmap (v1.0.12) and ggplot2 (v3.3.2) were used to carry out plotting. For the basic environment, the operation system is Ubuntu 20.04 LTS, and the version of R is 3.6.3.</p>
    <p id="p0035">To calculate the rate of antibody response for each protein, the mean plus 2 times standard deviation (SD) of the control serum was set as the cut-off. R was used for most data analysis and drawing, <italic>i.e.</italic>, Pearson correlation coefficient, receiver operating characteristic (ROC), T-test, cluster analysis, and machine learning.</p>
  </sec>
  <sec id="s0015">
    <title>Database content and usage</title>
    <sec id="s0020">
      <title>The database framework and clinical information for the patients</title>
      <p id="p0040">In this study, we collected 2360 serum samples from 783 patients (387 males and 396 females) with an average age of 61.4 years and average onset time of 50 days. Among these 783 patients, there were 369 mild, 309 severe, and 105 critical cases, with 723 cured and 60 dead (<xref rid="f0005" ref-type="fig">Figure 1</xref>A; <xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="s0065" ref-type="sec">Table S1</xref>).<fig id="f0005"><label>Figure 1</label><caption><p><bold>Overview of data resources and functional modules of COVID-ONE-hi</bold></p><p><bold>A.</bold> Patient information of the study cohort showing the distribution of gender, outcome, severity type, <italic>etc</italic>. <bold>B.</bold> The framework of COVID-ONE-hi. The COVID-ONE-hi, a one-stop database for COVID-19-specific humoral immune responses and clinical parameters, includes 223 protein/peptide antibody responses and 96 clinical parameters from 2360 serum samples collected from 783 COVID-19 patients. Using the Shiny package, COVID-ONE-hi provides single-group or paired-group analysis based on the dataset.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="t0005"><label>Table 1</label><caption><p><bold>The clinical information of involved patients</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"><bold>Group</bold></th><th><bold>COVID-19</bold></th></tr></thead><tbody><tr><td colspan="2">Number of patients</td><td>783</td></tr><tr><td colspan="2">Number of serum samples</td><td>2360</td></tr><tr><td colspan="2">Age (year)</td><td>61.4 ± 14.5</td></tr><tr><td>Gender</td><td>Male<break/>Female</td><td>387<break/>396</td></tr><tr><td>Severity/outcome</td><td>Mild<break/>Severe<break/>Critical</td><td>369<break/>309<break/>105</td></tr><tr><td>Outcome</td><td>Cured<break/>Death</td><td>723<break/>60</td></tr><tr><td colspan="2">Source</td><td>Tongji Hospital, Wuhan, China</td></tr></tbody></table></table-wrap></p>
      <p id="p0045">To systematically analyze immune responses to SARS-CoV-2 infection, we screened 2360 serum samples using SARS-CoV-2 protein microarray that contains 24 full-length/truncated proteins corresponding to 20 known SARS-CoV-2 proteins and 199 peptides fully covering the spike protein. Additionally, we analyzed 89 blood parameters for the 2360 serum samples (including complete blood count, blood chemistry study, and blood enzyme tests). Hence, we obtained a comprehensive dataset that contains COVID-19-specific humoral immune responses and clinical parameters.</p>
      <p id="p0050">By combining clinical information, IgG/IgM immune responses, and blood parameters, we established a database (COVID-ONE-hi) that provides a one-stop analysis pipeline for COVID-19-specific humoral immune responses and clinical parameters (<xref rid="f0005" ref-type="fig">Figure 1</xref>B). To help users obtain more COVID-19 serum profiling data, we set up a page on the COVID-ONE-hi website, named “More studies”, to archive other highly related data of COVID-19 serum profiling (protein/peptide microarray/phage display) <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>. In addition, a healthy control dataset was added to the “HELP” page, which contains the IgG and IgM responses for 528 healthy people against the 24 full-length/truncated proteins and 199 spike protein peptides (<xref rid="s0065" ref-type="sec">Table S2</xref>).</p>
      <p id="p0055">The following three steps are included in the analysis module: users select a set of samples in the panel of patient information and click “START”; COVID-ONE-hi filters candidate samples according to the given parameters; and COVID-ONE-hi conducts analysis and provides results on the webpage.</p>
      <p id="p0060">To demonstrate how to use COVID-ONE-hi for analysis, we provide two cases for single group and paired groups as examples.</p>
    </sec>
    <sec id="s0025">
      <title>Case I: antibody responses and clinical parameters of dead COVID-19 patients</title>
      <p id="p0065">To study the features of dead COVID-19 patients, we selected the “death” parameter of outcome in a single-group analysis module. This cohort contained 392 serum samples from 60 patients (38 male <italic>vs.</italic> 22 female), with an average age of 69.6 years (<xref rid="t0010" ref-type="table">Table 2</xref>). The IgG response landscape analysis of SARS-CoV-2 proteins showed that the positive rates of S1 subunit of spike protein (S1 protein), N protein, and ORF3b were 95%, 93%, and 87%, respectively, which are consistent with previous studies <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref> (<xref rid="f0010" ref-type="fig">Figure 2</xref>A). Interestingly, NSP7 had  a IgG-positive rate of 88%, suggesting that NSP7 may play an important role in COVID-19 (<xref rid="f0010" ref-type="fig">Figure 2</xref> A). In addition, the spike peptide S1-45 had the highest positive rate (87%) for the IgM response, indicating that the region including S1-45 may play an important role in IgM immunity (<xref rid="s0065" ref-type="sec">Figure S1</xref>).<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p><bold>Serum sample information of Case</bold><bold>I</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"><bold>Group</bold></th><th><bold>COVID-19</bold></th></tr></thead><tbody><tr><td colspan="2">Number of patients</td><td>60</td></tr><tr><td colspan="2">Number of serum samples</td><td>392</td></tr><tr><td colspan="2">Age (year)</td><td>69.6 ± 10.3</td></tr><tr><td>Gender</td><td>Male<break/>Female</td><td>38<break/>22</td></tr><tr><td>Severity</td><td>Mild<break/>Severe<break/>Critial</td><td>0<break/>2<break/>58</td></tr><tr><td>Outcome</td><td>Cured<break/>Death</td><td>0<break/>60</td></tr><tr><td colspan="2">Source</td><td>Tongji Hospital, Wuhan, China</td></tr></tbody></table></table-wrap><fig id="f0010"><label>Figure 2</label><caption><p><bold>SARS-CoV-2-specific antibody responses and their correlations with clinical parameters</bold><bold>for</bold><bold>COVID-19 non-survivors</bold></p><p><bold>A.</bold> The IgG response landscapes against SARS-CoV-2 proteins (upper), S1 protein peptides (middle), and S2 protein peptides (lower). <bold>B.</bold> Heatmap showing correlation analysis of blood parameters. <bold>C.</bold> Heatmap showing correlation analysis of IgG responses against SARS-CoV-2 proteins. <bold>D.</bold> Scatter plots showing correlations between the S1 IgG response and the N-Cter IgG response / globulin. S1 protein, S1 subunit of spike protein; S2 protein, S2 subunit of spike protein; N protein1, full-length N protein purified by cell-free system; N protien2, full-length N protein purified by prokaryotic system; N-Nter, N-ternimus of N protein purified by cell-free system; N-Cter, C-ternimus of N protein purified by cell-free system.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0070">Correlation analysis of clinical parameters showed that the neutrophil count had negative correlations with the monocyte count and the lymphocyte ratio (<xref rid="f0010" ref-type="fig">Figure 2</xref>B). In addition, correlation analysis of IgG responses showed high correlations between S1 IgG response and IgG responses of full-length/truncated N proteins, with S1 IgG response and N-Cter IgG response showing the highest correlation (<xref rid="f0010" ref-type="fig">Figure 2</xref>C and D). To study influencing factors of S1 antibody production, we analyzed the correlation between the S1 IgG response and clinical parameters, and found that S1 IgG response correlated with globulin (<xref rid="f0010" ref-type="fig">Figure 2</xref>D).</p>
    </sec>
    <sec id="s0030">
      <title>Case II: differences in IgG/IgM immune responses and clinical parameters associated with gender</title>
      <p id="p0075">Previous studies have shown that gender has considerable effect on the severity and outcome of COVID-19 <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref> and is associated with underlying differences in immune responses to infection <xref rid="b0120" ref-type="bibr">[24]</xref>. To study differences in IgG/IgM immune responses and clinical parameters between the genders, we defined males as Group 1 and females as Group 2 for severe and critical patients, with 231 males at average age of 64.3 and 183 females at average age of 68.1. Consistent with previous studies <xref rid="b0125" ref-type="bibr">[25]</xref>, males had a higher risk of severe/critical COVID-19 than females (231/387 <italic>vs.</italic> 183/396, <italic>P</italic> &lt; 0.001) (<xref rid="t0015" ref-type="table">Tables 3</xref> and <xref rid="t0020" ref-type="table">4</xref>).<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p><bold>Serum sample information of Case</bold><bold>II</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"><bold>Group</bold></th><th><bold>Group 1</bold></th><th><bold>Group 2</bold></th></tr></thead><tbody><tr><td colspan="2">Number of patients</td><td>231</td><td>183</td></tr><tr><td colspan="2">Number of serum samples</td><td>949</td><td>684</td></tr><tr><td colspan="2">Age (year)</td><td>64.3 ± 12.4</td><td>68.1 ± 11.9</td></tr><tr><td>Gender</td><td>Male<break/>Female</td><td>231<break/>0</td><td>0<break/>183</td></tr><tr><td>Severity</td><td>Mild<break/>Severe<break/>Critical</td><td>0<break/>165<break/>66</td><td>0<break/>144<break/>39</td></tr><tr><td>Outcome</td><td>Cured<break/>Death</td><td>193<break/>38</td><td>161<break/>22</td></tr><tr><td colspan="2">Source</td><td colspan="2">Tongji Hospital, Wuhan, China</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0020"><label>Table 4</label><caption><p><bold>The binary logistic regression parameter of severity in association with the gender among COVID-19 patients</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle"><bold>Gender</bold></th><th colspan="5" align="center"><bold>Severity</bold><hr/></th></tr><tr><th><bold>β</bold></th><th><bold>S</bold><bold>EM</bold></th><th><bold>Wald c2</bold></th><th><bold>OR (95% CI)</bold></th><th><bold><italic>P</italic></bold></th></tr></thead><tbody><tr><td>Female</td><td>−</td><td>−</td><td>−</td><td>1</td><td>−</td></tr><tr><td>Male</td><td align="char">0.544</td><td align="char">0.145</td><td align="char">14.180</td><td>1.724 (1.298, 2.288)</td><td align="char">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note</italic>: SEM, standard error of mean; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></p>
      <p id="p0080">UMAP analysis showed no overall difference in IgG immunity between 387 males and 396 females (<xref rid="f0015" ref-type="fig">Figure 3</xref>A). To explore the disease mechanism in the genders, we performed in-depth analyses for antibody responses and blood parameters using COVID-ONE-hi. The antibody response landscape showed that male patients had higher IgG-positive rates than females for ORF9b, RdRp, and NSP1 (<xref rid="f0015" ref-type="fig">Figure 3</xref>B)<italic>.</italic> Moreover, longitudinal antibody dynamic analysis showed that males had a stronger ORF9b IgG response during the whole period of symptom onset, with a stronger NSP1 IgG response during the early stage of symptom onset, but had no significant difference in RdRp IgG response compared with females (<xref rid="f0015" ref-type="fig">Figure 3</xref>C). ORF9b has been considered a drug target for the treatment of COVID-19 because it suppresses type I interferon responses <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>. To explore the relevance between ORF9b antibody responses and COVID-19 severity, we compared ORF9b IgG responses between mild and severe/critical cases in different genders, and the results showed that higher ORF9b IgG response was observed in severe/critical cases than in mild cases in males, whereas no significant difference was observed between mild and severe/critical cases in females (<xref rid="f0015" ref-type="fig">Figure 3</xref>D).<fig id="f0015"><label>Figure 3</label><caption><p><bold>Correlation of the ORF</bold><bold>9b IgG response with COVID-19 severity in male patients</bold></p><p><bold>A.</bold> Scatter plot showing UMAP results for serum samples using IgG/IgM responses to 24 full-length/truncated proteins (corresponding to 20 known SARS-CoV-2 proteins) in gender subgroup analysis. <bold>B</bold><bold>.</bold> Histogram showing IgG-positive rates of different SARS-CoV-2 proteins and spike protein peptides in males and females. <bold>C.</bold> Scatter plots showing the dynamic IgG responses of ORF9b (left), NSP1 (middle), and RdRp (right) using longitudinal samples from male and female patients. <bold>D</bold><bold>.</bold> Scatter plots showing the dynamic ORF9b IgG response in male (left) and female (right) COVID-19 patients with mild and severe/critical symptoms. <italic>P</italic> value was calculated by a two-sided <italic>t</italic>-test. UMAP, uniform manifold approximation and projection.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0085">To further decipher differences between female and male patients of COVID-19, we employed random forest for machine learning. The results showed creatinine, which is an acute kidney injury marker, to be the most significant factor between males and females (<xref rid="f0020" ref-type="fig">Figure 4</xref>A). To explore the relevance between creatinine and gender in COVID-19, we compared the median and dynamic creatinine levels between males and females, and observed that both the median and dynamic creatinine levels in males were significantly higher than those in females (<xref rid="f0020" ref-type="fig">Figure 4</xref>B and C). To explore the relevance between creatinine and COVID-19 severity, we compared the dynamic creatinine levels between mild and severe/critical cases in males and females, respectively. Similar to ORF9b IgG responses, male patients with severe/critical COVID-19 symptoms had a higher level of creatinine (<xref rid="f0020" ref-type="fig">Figure 4</xref>D). Hence, ORF9b antibodies and creatinine are associated with severe/critical symptoms in male COVID-19 patients, which suggests different pathogeneses and complications between male and female COVID-19 patients.<fig id="f0020"><label>Figure 4</label><caption><p><bold>Correlation of creatinine response with COVID-19 severity in male patients</bold></p><p><bold>A.</bold> The top 15 gender-specific parameters by random forest analysis ranked by the mean decrease in accuracy (left) and Gini coefficient (right). <bold>B.</bold> Boxplot showing the significant difference of median creatinine levels in gender subgroup analysis. <bold>C.</bold> Scatter plot showing the dynamic creatinine levels for male and female COVID-19 patients. <bold>D.</bold> Scatter plots showing the dynamic creatinine levels for male (left) and female (right) COVID-19 patients with mild and severe/critical symptoms. <italic>P</italic> value was calculated by a two-sided <italic>t</italic>-test.</p></caption><graphic xlink:href="gr4"/></fig></p>
    </sec>
  </sec>
  <sec id="s0035">
    <title>Discussion and perspectives</title>
    <p id="p0090">In this study, we built COVID-ONE-hi, a COVID-19-specific database, using R Shiny. COVID-ONE-hi is based on a comprehensive dataset generated by analyzing 2360 COVID-19 sera using the SARS-CoV-2 protein microarray containing 24 full-length/truncated proteins corresponding to 20 of the 28 known SARS-CoV-2 proteins and 199 peptides completely covering the entire spike protein sequence.</p>
    <p id="p0095">There are several published studies identifying the clinical characteristics, biomarkers, and specific antibody responses of diverse COVID-19 patients (<xref rid="s0065" ref-type="sec">Table S3</xref>). To strengthen the credibility of our dataset, we compared SARS-CoV-2-specific antibody responses with other studies at different levels. At the protein level, we analyzed the dynamic response to the S1 and N proteins. The results showed that the responses to S1 and N proteins peaked at 6 weeks after the onset of symptoms for IgG and 4 weeks for IgM, which is consistent with the results of previous studies <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref> (<xref rid="s0065" ref-type="sec">Figure S2</xref>). At the peptide level, we compared IgG recognition of immunodominant regions in the SARS-CoV-2 spike protein and found that some high response areas that we identified <xref rid="b0060" ref-type="bibr">[12]</xref> are consistent with those identified by Shrock et al. <xref rid="b0070" ref-type="bibr">[14]</xref>: aa 25–36, aa 553–588, aa 770–829, aa 1148–1159, and aa 1256–1273. And another hot spot (aa 451–474) was only detected in our study. Regarding antibody diagnosis, Assia et al. <xref rid="b0095" ref-type="bibr">[19]</xref> achieved an area under the curve (AUC) value of 0.986 for IgG and 0.988 for IgM for the detection of prior SARS-CoV-2 infection when combining N and spike proteins. In our study, the AUC values of the N protein for IgG and IgM are 0.995 and 0.988, respectively, and the AUC values of the S1 protein  for IgG and IgM are 0.992 and 0.992, respectively. We also found that S2-78 (aa 1148–1159) IgG is comparable to S1 IgG for COVID-19 patients, with an AUC value of 0.99 for IgG and 0.953 for IgM <xref rid="b0055" ref-type="bibr">[11]</xref>.</p>
    <p id="p0100">To our knowledge, COVID-ONE-hi is the first database for COVID-19-specific immune responses enriched in clinical parameters and has the following features. 1) Universality: COVID-ONE-hi contains 783 COVID-19 patients that have been classified by their medical history (<xref rid="s0065" ref-type="sec">Table S4</xref>), and thus will be of broad interest for researchers and clinicians from diverse backgrounds. 2) Accessibility: COVID-ONE-hi provides a one-stop analysis pipeline, by which users can easily obtain meaningful information. 3) Scalability: COVID-ONE-hi is built on the R platform, which is freely accessible, and many modular tools are readily available; thus, we can easily expand and incorporate new analyses for the dataset whenever necessary without changing the overall structure of the database. Nonetheless, there are some limitations for COVID-ONE-hi. For example, it lacks data for convalescent patients, peptide-level humoral responses to proteins other than S protein, and multicentre samples. In the future, we will analyze the dynamic responses of SARS-CoV-2-specific antibodies using ∼ 500 serum samples from ∼ 100 COVID-19 convalescent patients. We will also integrate published peptide microarray/phage display-related data <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref> and attempt to update the database covering the whole SARS-CoV-2 proteome at the peptide or amino acid level. In addition, the SARS-CoV-2 protein microarray has already been promoted by CDI Labs (<ext-link ext-link-type="uri" xlink:href="http://www.cdi.bio" id="ir020">www.cdi.bio</ext-link>) and ArrayJet (<ext-link ext-link-type="uri" xlink:href="http://www.arrayjet.co.uk" id="ir025">www.arrayjet.co.uk</ext-link>), and we anticipate more diverse data for SARS-CoV-2-specific antibody responses from multicentre samples. We strongly believe that by sharing a large dataset and facilitating data analysis, COVID-ONE-hi will be a valuable resource for COVID-19 research.</p>
  </sec>
  <sec id="s0040">
    <title>Ethical statement</title>
    <p id="p0105">The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (ITJ-C20200128). Written informed consent was obtained from all participants enrolled in this study.</p>
  </sec>
  <sec sec-type="data-availability" id="s0045">
    <title><bold>Data</bold> availability</title>
    <p id="p0110">COVID-ONE-hi is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://www.covid-one.cn" id="ir030">www.covid-one.cn</ext-link>. If users need the raw data of antibody responses or clinical parameters, please contact the corresponding author (<ext-link ext-link-type="uri" xlink:href="http://taosc%40sjtu.edu.cn" id="ir040">taosc@sjtu.edu.cn</ext-link>).</p>
  </sec>
  <sec id="s0055">
    <title>CRediT author statement</title>
    <p id="p0120"><bold>Zhaowei Xu:</bold> Software, Formal analysis, Writing - original draft. <bold>Yang Li:</bold> Methodology, Formal analysis, Investigation. <bold>Qing Lei:</bold> Methodology, Formal analysis, Investigation. <bold>Likun Huang:</bold> Software. <bold>Dan-yun Lai:</bold> Methodology, Formal analysis, Validation, Investigation. <bold>Shu-juan Guo:</bold> Methodology, Formal analysis. <bold>He-wei Jiang:</bold> Methodology, Investigation. <bold>Hongyan Hou:</bold> Resources. <bold>Yun-xiao Zheng:</bold> Formal analysis. <bold>Xue-ning Wang:</bold> Formal analysis. <bold>Jiaoxiang Wu:</bold> Resources. <bold>Ming-liang Ma:</bold> Formal analysis. <bold>Bo Zhang:</bold> Resources. <bold>Hong Chen:</bold> Formal analysis. <bold>Caizheng Yu:</bold> Resources. <bold>Jun-biao Xue:</bold> Formal analysis. <bold>Hai-nan Zhang:</bold> Methodology, Investigation. <bold>Huan Qi:</bold> Formal analysis. <bold>Siqi Yu:</bold> Formal analysis. <bold>Mingxi Lin:</bold> Formal analysis. <bold>Yandi Zhang:</bold> Investigation. <bold>Xiaosong Lin:</bold> Investigation. <bold>Zongjie Yao:</bold> Investigation. <bold>Huiming Sheng:</bold> Resources. <bold>Ziyong Sun:</bold> Investigation. <bold>Feng Wang:</bold> Resources. <bold>Xionglin Fan:</bold> Conceptualization, Investigation. <bold>Sheng-ce Tao:</bold> Conceptualization, Methodology, Writing - review &amp; editing, Supervision. All authors have read and approved the final manuscript.</p>
  </sec>
  <sec id="s0050">
    <title>Competing interests</title>
    <p id="p0115">The authors declare no competing interests.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Gardner</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title>
        <source>Lancet Infect Dis</source>
        <volume>20</volume>
        <year>2020</year>
        <fpage>533</fpage>
        <lpage>534</lpage>
        <pub-id pub-id-type="pmid">32087114</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Knipe</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Levy</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Fitzgerald</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Mühlberger</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Ensuring vaccine safety</article-title>
        <source>Science</source>
        <volume>370</volume>
        <year>2020</year>
        <fpage>eabf0357</fpage>
      </element-citation>
    </ref>
    <ref id="b0015">
      <label>3</label>
      <element-citation publication-type="journal" id="h0015">
        <person-group person-group-type="author">
          <name>
            <surname>Lipsitch</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dean</surname>
            <given-names>N.E.</given-names>
          </name>
        </person-group>
        <article-title>Understanding COVID-19 vaccine efficacy</article-title>
        <source>Science</source>
        <volume>370</volume>
        <year>2020</year>
        <fpage>763</fpage>
        <lpage>765</lpage>
        <pub-id pub-id-type="pmid">33087460</pub-id>
      </element-citation>
    </ref>
    <ref id="b0020">
      <label>4</label>
      <element-citation publication-type="journal" id="h0020">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zuiani</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Fischinger</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Mullur</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Atyeo</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Travers</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>1496</fpage>
        <lpage>1507.e16</lpage>
        <pub-id pub-id-type="pmid">33171099</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>5</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Peng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Mentzer</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19</article-title>
        <source>Nat Immunol</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>1336</fpage>
        <lpage>1345</lpage>
        <pub-id pub-id-type="pmid">32887977</pub-id>
      </element-citation>
    </ref>
    <ref id="b0030">
      <label>6</label>
      <element-citation publication-type="journal" id="h0030">
        <person-group person-group-type="author">
          <name>
            <surname>Cox</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Brokstad</surname>
            <given-names>K.A.</given-names>
          </name>
        </person-group>
        <article-title>Not just antibodies: B cells and T cells mediate immunity to COVID-19</article-title>
        <source>Nat Rev Immunol</source>
        <volume>20</volume>
        <year>2020</year>
        <fpage>581</fpage>
        <lpage>582</lpage>
        <pub-id pub-id-type="pmid">32839569</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>7</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>H.W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.N.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses</article-title>
        <source>Nat Commun</source>
        <volume>11</volume>
        <year>2020</year>
        <fpage>3581</fpage>
        <pub-id pub-id-type="pmid">32665645</pub-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>8</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>D.Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.N.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>H.W.</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>M.L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients</article-title>
        <source>Cell Mol Immunol</source>
        <volume>17</volume>
        <year>2020</year>
        <fpage>1095</fpage>
        <lpage>1097</lpage>
        <pub-id pub-id-type="pmid">32895485</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>9</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>Lei</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>C.z.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>H.y.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Z.w.</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>Z.j.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Anti-SARS-CoV-2 IgG responses are powerful predicting signatures for the outcome of COVID-19 patients</article-title>
        <source>J Adv Res</source>
        <volume>36</volume>
        <year>2022</year>
        <fpage>133</fpage>
        <lpage>145</lpage>
        <pub-id pub-id-type="pmid">35116173</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>10</label>
      <element-citation publication-type="journal" id="h0050">
        <person-group person-group-type="author">
          <name>
            <surname>Lei</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>H.Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>Z.Q.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections</article-title>
        <source>Allergy</source>
        <volume>76</volume>
        <year>2021</year>
        <fpage>551</fpage>
        <lpage>561</lpage>
        <pub-id pub-id-type="pmid">33040337</pub-id>
      </element-citation>
    </ref>
    <ref id="b0055">
      <label>11</label>
      <element-citation publication-type="journal" id="h0055">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>D.Y.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Z.W.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients</article-title>
        <source>Cell Mol Immunol</source>
        <volume>18</volume>
        <year>2021</year>
        <fpage>621</fpage>
        <lpage>631</lpage>
        <pub-id pub-id-type="pmid">33483707</pub-id>
      </element-citation>
    </ref>
    <ref id="b0060">
      <label>12</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>M.l.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>D.y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients</article-title>
        <source>Cell Rep</source>
        <volume>34</volume>
        <year>2021</year>
        <fpage>108915</fpage>
        <pub-id pub-id-type="pmid">33761319</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>13</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>D.Y.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>H.W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins</article-title>
        <source>Cell Rep</source>
        <volume>36</volume>
        <year>2021</year>
        <fpage>109391</fpage>
        <pub-id pub-id-type="pmid">34242574</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>14</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Shrock</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Fujimura</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Kula</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Timms</surname>
            <given-names>R.T.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>I.H.</given-names>
          </name>
          <name>
            <surname>Leng</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity</article-title>
        <source>Science</source>
        <volume>370</volume>
        <year>2020</year>
        <fpage>eabd4250</fpage>
        <pub-id pub-id-type="pmid">32994364</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>15</label>
      <element-citation publication-type="journal" id="h0075">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution</article-title>
        <source>ACS Cent Sci</source>
        <volume>6</volume>
        <year>2020</year>
        <fpage>2238</fpage>
        <lpage>2249</lpage>
        <pub-id pub-id-type="pmid">33372199</pub-id>
      </element-citation>
    </ref>
    <ref id="b0080">
      <label>16</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>Schwarz</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Heiss</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Mahendran</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Casilag</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Kurth</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>L.E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 proteome-wide analysis revealed significant epitope signatures in COVID-19 patients</article-title>
        <source>Front Immunol</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>629185</fpage>
        <pub-id pub-id-type="pmid">33833755</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>17</label>
      <element-citation publication-type="journal" id="h0085">
        <person-group person-group-type="author">
          <name>
            <surname>Holenya</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>P.J.</given-names>
          </name>
          <name>
            <surname>Reimer</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Woltersdorf</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Panterodt</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Glas</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development</article-title>
        <source>Eur J Immunol</source>
        <volume>51</volume>
        <year>2021</year>
        <fpage>1839</fpage>
        <lpage>1849</lpage>
        <pub-id pub-id-type="pmid">33772767</pub-id>
      </element-citation>
    </ref>
    <ref id="b0090">
      <label>18</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19</article-title>
        <source>Nat Commun</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>1813</fpage>
        <pub-id pub-id-type="pmid">33753738</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>19</label>
      <element-citation publication-type="journal" id="h0095">
        <person-group person-group-type="author">
          <name>
            <surname>de Assis</surname>
            <given-names>R.R.</given-names>
          </name>
          <name>
            <surname>Jain</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nakajima</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Jasinskas</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Felgner</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Obiero</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray</article-title>
        <source>Nat Commun</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>6</fpage>
        <pub-id pub-id-type="pmid">33397903</pub-id>
      </element-citation>
    </ref>
    <ref id="b0100">
      <label>20</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Long</surname>
            <given-names>Q.X.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>B.Z.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>H.J.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>G.C.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>
        <source>Nat Med</source>
        <volume>26</volume>
        <year>2020</year>
        <fpage>845</fpage>
        <lpage>848</lpage>
        <pub-id pub-id-type="pmid">32350462</pub-id>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>21</label>
      <element-citation publication-type="journal" id="h0105">
        <person-group person-group-type="author">
          <name>
            <surname>Hachim</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kavian</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Chin</surname>
            <given-names>A.W.H.</given-names>
          </name>
          <name>
            <surname>Chu</surname>
            <given-names>D.K.W.</given-names>
          </name>
          <name>
            <surname>Mok</surname>
            <given-names>C.K.P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection</article-title>
        <source>Nat Immunol</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>1293</fpage>
        <lpage>1301</lpage>
        <pub-id pub-id-type="pmid">32807944</pub-id>
      </element-citation>
    </ref>
    <ref id="b0110">
      <label>22</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Williamson</surname>
            <given-names>E.J.</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Bhaskaran</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Bacon</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bates</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Morton</surname>
            <given-names>C.E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title>
        <source>Nature</source>
        <volume>584</volume>
        <year>2020</year>
        <fpage>430</fpage>
        <lpage>436</lpage>
        <pub-id pub-id-type="pmid">32640463</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>23</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Scully</surname>
            <given-names>E.P.</given-names>
          </name>
          <name>
            <surname>Haverfield</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ursin</surname>
            <given-names>R.L.</given-names>
          </name>
          <name>
            <surname>Tannenbaum</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>S.L.</given-names>
          </name>
        </person-group>
        <article-title>Considering how biological sex impacts immune responses and COVID-19 outcomes</article-title>
        <source>Nat Rev Immunol</source>
        <volume>20</volume>
        <year>2020</year>
        <fpage>442</fpage>
        <lpage>447</lpage>
        <pub-id pub-id-type="pmid">32528136</pub-id>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>24</label>
      <element-citation publication-type="journal" id="h0120">
        <person-group person-group-type="author">
          <name>
            <surname>Takahashi</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Ellingson</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Israelow</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Lucas</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Sex differences in immune responses that underlie COVID-19 disease outcomes</article-title>
        <source>Nature</source>
        <volume>588</volume>
        <year>2020</year>
        <fpage>315</fpage>
        <lpage>320</lpage>
        <pub-id pub-id-type="pmid">32846427</pub-id>
      </element-citation>
    </ref>
    <ref id="b0125">
      <label>25</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>
        <source>Lancet</source>
        <volume>395</volume>
        <year>2020</year>
        <fpage>507</fpage>
        <lpage>513</lpage>
        <pub-id pub-id-type="pmid">32007143</pub-id>
      </element-citation>
    </ref>
    <ref id="b0130">
      <label>26</label>
      <element-citation publication-type="journal" id="h0130">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>H.W.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.N.</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>Q.F.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70</article-title>
        <source>Cell Mol Immunol</source>
        <volume>17</volume>
        <year>2020</year>
        <fpage>998</fpage>
        <lpage>1000</lpage>
        <pub-id pub-id-type="pmid">32728199</pub-id>
      </element-citation>
    </ref>
    <ref id="b0135">
      <label>27</label>
      <element-citation publication-type="journal" id="h0135">
        <person-group person-group-type="author">
          <name>
            <surname>Gordon</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Hiatt</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bouhaddou</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rezelj</surname>
            <given-names>V.V.</given-names>
          </name>
          <name>
            <surname>Ulferts</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Braberg</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms</article-title>
        <source>Science</source>
        <volume>370</volume>
        <year>2020</year>
        <fpage>eabe9403</fpage>
        <pub-id pub-id-type="pmid">33060197</pub-id>
      </element-citation>
    </ref>
    <ref id="b0140">
      <label>28</label>
      <element-citation publication-type="journal" id="h0140">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Qin</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Olieric</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions</article-title>
        <source>Nat Commun</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>2843</fpage>
        <pub-id pub-id-type="pmid">33990585</pub-id>
      </element-citation>
    </ref>
    <ref id="b0145">
      <label>29</label>
      <element-citation publication-type="journal" id="h0145">
        <person-group person-group-type="author">
          <name>
            <surname>Qi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>H.W.</given-names>
          </name>
          <name>
            <surname>Ling</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L.Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.N.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution</article-title>
        <source>Cell Mol Immunol</source>
        <volume>18</volume>
        <year>2021</year>
        <fpage>1067</fpage>
        <lpage>1069</lpage>
        <pub-id pub-id-type="pmid">33664486</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="s0065" sec-type="supplementary-material">
    <title>Supplementary material</title>
    <p id="p0135">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0035"><caption><title>Supplementary File S1</title><p>The methods of protein microarray construction and serum profiling.</p></caption><media xlink:href="mmc1.docx"/></supplementary-material></p>
    <p id="p0140">
      <supplementary-material content-type="local-data" id="m0030">
        <caption>
          <title>Supplementary Figure S1</title>
          <p>The antibody IgM response landscape against SARS-CoV-2 proteins (upper part), S1 protein peptides (middle part) and S2 protein peptides (lower part).</p>
        </caption>
        <media xlink:href="mmc2.pptx"/>
      </supplementary-material>
    </p>
    <p id="p0145">
      <supplementary-material content-type="local-data" id="m0025">
        <caption>
          <title>Supplementary Figure S2</title>
          <p><bold>Dynamic antibody responses to S1 and N proteins</bold> Scatter plot shows dynamic antibody responses to S1 protein IgG <bold>(A)</bold>, N protein IgG <bold>(B)</bold>, S1 protein IgM <bold>(C)</bold>, and N protein IgM <bold>(D)</bold>.</p>
        </caption>
        <media xlink:href="mmc3.pptx"/>
      </supplementary-material>
    </p>
    <p id="p0150">
      <supplementary-material content-type="local-data" id="m0020">
        <caption>
          <title>Supplementary Table S1</title>
        </caption>
        <media xlink:href="mmc4.xlsx"/>
      </supplementary-material>
    </p>
    <p id="p0155">
      <supplementary-material content-type="local-data" id="m0015">
        <caption>
          <title>Supplementary Table S2</title>
        </caption>
        <media xlink:href="mmc5.xlsx"/>
      </supplementary-material>
    </p>
    <p id="p0160">
      <supplementary-material content-type="local-data" id="m0010">
        <caption>
          <title>Supplementary Table S3</title>
        </caption>
        <media xlink:href="mmc6.xlsx"/>
      </supplementary-material>
    </p>
    <p id="p0165">
      <supplementary-material content-type="local-data" id="m0005">
        <caption>
          <title>Supplementary Table S4</title>
        </caption>
        <media xlink:href="mmc7.xlsx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ak005">
    <title>Acknowledgments</title>
    <p id="p0125">This work was partially supported by the National Key R&amp;D Program of China Grant (Grant No. 2016YFA0500600) and the National Natural Science Foundation of China (Grant Nos. 31970130, 31600672, 31900112, 21907065, and 32000027).</p>
  </ack>
  <fn-group>
    <fn id="d35e451">
      <p id="np005">Peer review under responsibility of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.</p>
    </fn>
    <fn id="s0060" fn-type="supplementary-material">
      <p id="p0130">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gpb.2021.09.006" id="ir045">https://doi.org/10.1016/j.gpb.2021.09.006</ext-link>.</p>
    </fn>
  </fn-group>
</back>
